吴息凤 - 浙江大学

个人简介

1984年获复旦大学（原上海第一医学院）医学学位，1987年获浙江大学（原浙江医科大学）硕士学位，1991年在法国获得博士后，1994年从德州大学公共卫生学院获得博士学位。1995年起至2019年任职于美国癌症医院历年排名第一的德州大学MD安德森癌症中心，兼任德克萨斯大学公共卫生学院流行病学教授。2004年开始授予终身教授，2006年开始授予Ashbel Smith Professorship冠名教授，2008年起至2019获得癌症预防Betty B. Marcus冠名主席，2010年起至2019担任癌前基因组图谱计划主任，转化医学和公众健康基因组学中心主任包括血液样本库和个体化风险预测项目，2011年起至2019担任病史数据库主任。2011年起至2015担任流行病学系系主任和流行病学学科负责人。作为一名拥有多学科知识背景和创新理念的科学家，吴教授使用高度创新，循证医学，和整合的战略建立一系列的大数据，大型样本库，发现和验证可改变肿瘤危险因素，筛选癌症药物遗传生物标志物，利用高端的生物信息和生物统计方法建立整合性的风险预测模型并转成一系列的基于互联网的个人预测模型的人工智能工具，建立高危人群早期识别方法，为制定有针对性个体化的精准肿瘤预防和治疗领域做出了卓越的贡献，她领导的团队成为该领域的世界顶尖团队之一。

研究领域

肿瘤分子流行病学，健康医疗大数据，生物标志物，精准医学，风险预测人工智能

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Project Leader, University of Texas LUNG SPORE – Project 2: Epidemiologic Studies of Germline Polymorphisms in miRNA Pathways to Determine Their Role in Risk of Lung Cancer Development and Recurrence, P50 CA070907, NIH/NCI, ~ $1,120,000 2. Principal Investigator-MDACC, Breast Cancer Genetic Study in African Ancestry Populations, R01 CA202981, Vanderbilt University - NIH/NCI, 7/1/2016-6/30/2021， ~$60，000 3. Principal Investigator, Epigenetic miRNA, SNP Signatures, and their Functions in Lung Cancer Outcomes, R01 CA176568, NIH/NCI, 4/1/2014-2/28/2019, ~$1,564,436 4. Principal Investigator, PQ-A4 Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-Chip, R01 CA180083, NIH/NCI, 9/10/2013-6/30/2018, ~$2,707,563 5. Principal Investigator, Molecular Pathways Linking Obesity and RCC Tumorigenesis (PQ1), R01 CA170298, NIH/NCI, 9/1/2012-6/30/2018, ~$2,800,000 6. Principal Investigator-MDACC, Genetic Epidemiology of non-Hodgkin Lymphoma, R01 CA200703, Mayo Clinic - NIH/NCI, 7/8/2016-5/31/2021, ~$551,630 7. Principal Investigator, Role of MicroRNA in Lung Cancer Risk & Clinical Outcome Prediction, RP130502, Cancer Prevention & Research Institute of Texas (CPRIT), 6/1/2013-5/30/2017, ~$1,294,346 8. Principal Investigator-MDACC, Telomere Length and the Risk of Cancer and Diabetes: A Prospective Longitudinal Study, Sister Institution Network Fund, MD Anderson Cancer Center, 11/15/2011-11/14/2013, ~$100,000 9. Principal Investigator, Prostate SPORE: Project 5. Separating the Chaff from the Wheat: Identifying Patients at Minimal Risk for Prostate Cancer Progression, CA140388-04, NIH/NCI，9/1/2012-8/31/2014, ~$320,596 10. Multiple Principal Investigator, Transdisciplinary Research in Cancer of the Lung (TRICL), U19 CA148127, NIH/NCI, 7/9/2010-6/30/2014, ~$4,559,755 11. Principal Investigator - Project 2, University of Texas SPORE in Lung Cancer. Project 2: Risk Prediction for Platinum-based Chemotherapy and Radiotherapy Outcome in Non-Small Cell Lung Cancer Patients, P50 CA070907, NIH/NCI, 9/1/2009-8/31/2014, ~$1,120,000 12. Principal Investigator, Lung Cancer Chemoradiation: Predictors of Survival, CA111646-05S1, NIH/NCI, 2009-2010, ~$243,158 13. Principal Investigator - Project 2, University of Texas SPORE in Head and Neck Cancer, Project 2: Cancer Risk Assessment in Patients with Oral Premalignant Lesions: An Integrative Approach, P50 CA097007, NIH/NCI, 8/1/2008-7/31/2014, ~$1,323,521 14. Principal Investigator, Genetic Instability and Risk for Esophageal Carcinoma, R01 CA111922, NIH/NCI, 3/10/2008-1/31/2015, ~$2,860,710 15. Principal Investigator, Genome-Wide Association Analysis of Bladder Cancer, U01 CA127615, NIH/NCI, 4/1/2008-3/31/2015, ~$4,803,014 16. Principal Investigator: Project 2, GU SPORE Project 2. Markers of Susceptibility as Predictors of Bladder Cancer Recurrence, P50 CA091846, NIH/NCI, 9/25/2006-8/31/2012, ~$1,360,000 17. Principal Investigator: Project 4, Molecular Epidemiology and Pharmacogenomics in Oral Carcinogenesis, P01 CA106451, NIH/NCI, 8/1/2004-7/31/2009, ~$922,932 18. Principal Investigator, Genetic Susceptibility to Bladder Cancer, R01 CA074880, NIH/NCI, 2004-2009, ~$1,753,658